Tango Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
TNGX$24.30+6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity
(in thousands, except share amounts)
| Additional · Accumulated Other · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balance at December 31, 2025 | 135,940,454 | $136 | $948,971 | $224 | $(603,152) | $346,179 |
| Issuance of common stock under stock plans | 3,073,938 | 3 | 17,602 | — | — | 17,605 |
| At-the-market offerings, net of issuance costs | 5,148,151 | 5 | 62,773 | — | — | 62,778 |
| Stock-based compensation expense | — | — | 10,797 | — | — | 10,797 |
| Other comprehensive loss | — | — | — | (339) | — | (339) |
| Net loss | — | — | — | — | (45,514) | (45,514) |
| Balance at March 31, 2026 | 144,162,543 | $144 | $1,040,143 | $(115) | $(648,666) | $391,506 |
| Issuance of common stock under stock plans | 3,050,872 | 3 | 20,621 | — | — | 20,624 |
| Common shares issued in offering, net of issuance costs | 21,166,676 | 21 | 651,348 | — | — | 651,369 |
| Stock-based compensation expense | — | — | 16,892 | — | — | 16,892 |
| Other comprehensive loss | — | — | — | (518) | — | (518) |
| Net loss | — | — | — | — | (55,341) | (55,341) |
| Balance at June 30, 2026 | 168,380,091 | $168 | $1,729,004 | $(633) | $(704,007) | $1,024,532 |
| Issuance of common stock under stock plans | 826,221 | 1 | 3,044 | — | — | 3,045 |
| Common shares issued in offering, net of issuance costs | — | — | (41) | — | — | (41) |
| Stock-based compensation expense | — | — | 24,906 | — | — | 24,906 |
| Other comprehensive loss | — | — | — | (3,875) | — | (3,875) |
| Net loss | — | — | — | — | (68,394) | (68,394) |
| Balance at September 30, 2026 | 169,206,312 | $169 | $1,756,913 | $(4,508) | $(772,401) | $980,173 |
| Additional · AccumulatedOther · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balance at December 31, 2024 | 107,729,343 | $108 | $700,631 | $336 | $(501,558) | $199,517 |
| Issuance of common stock under stock plans | 378,547 | — | 2 | — | — | 2 |
| Stock-based compensation expense | — | — | 7,255 | — | — | 7,255 |
| Other comprehensive loss | — | — | — | (142) | — | (142) |
| Net loss | — | — | — | — | (39,876) | (39,876) |
| Balance at March 31, 2025 | 108,107,890 | $108 | $707,888 | $194 | $(541,434) | $166,756 |
| Issuance of common stock under stock plans | 422,873 | 1 | 580 | — | — | 581 |
| Exercise of pre-funded warrants | 2,340,486 | 2 | (2) | — | — | |
| Stock-based compensation expense | — | — | 6,570 | — | — | 6,570 |
| Other comprehensive loss | — | — | — | (100) | — | (100) |
| Net loss | — | — | — | — | (38,853) | (38,853) |
| Balance at June 30, 2025 | 110,871,249 | $111 | $715,036 | $94 | $(580,287) | $134,954 |
| Issuance of common stock under stock plans | 695,813 | 1 | 2,540 | — | — | 2,541 |
| Stock-based compensation expense | — | — | 6,625 | — | — | 6,625 |
| Other comprehensive income | — | — | — | 27 | — | 27 |
| Net income | — | — | — | — | 15,884 | 15,884 |
| Balance at September 30, 2025 | 111,567,062 | $112 | $724,201 | $121 | $(564,403) | $160,031 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.